Tencent-backed WeDoctor, ophthalmic hospital Chaoju Eye Care aim to raise funds through initial public offerings in Hong Kong, sources say
- Tencent-backed WeDoctor’s target to submit listing application in HK for at least US$1 billion, a source said
- Health care groups in China are riding on HK IPO frenzy, as the city’s bourse raises record proceeds in January and February

More Chinese health care operators are seeking to kick off their initial public offerings (IPO) in Hong Kong during the first half, as Tencent-backed WeDoctor and ophthalmic hospital group Chaoju Eye Care are seeking to move their listing applications forward within these two months.
But the listing plan could see a revival for WeDoctor. Wang Yongcai has taken over as chief financial officer. Bloomberg reported in February that Jeff Chen rejoined WeDoctor as chief strategy officer looking after the firm’s capital market functions, a role that he had held before his departure from the firm in early 2019.
WeDoctor did not immediately respond to enquiries by South China Morning Post. JPMorgan Chase & Co., CMB International and Citi are arranging the share sale. These banks were either not immediately available for comment or declined commenting.
